For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.

FDA Approves the First Drug for Alzheimer's Agitation: Rexulti

Leqembi Granted Full FDA Approval to Treat Early Alzheimer's Disease

Lundbeck and Otsuka reports positive data from phase 3 trial of

First FDA Approved Medication for Agitation Associated with

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Medications for Memory Loss

FDA Approves First Drug to Treat Dementia-Associated Agitation in

FDA Approves First Drug to Treat Agitation Symptoms Associated

Antipsychotic Shows Benefit for Alzheimer's Agitation

FAQ for agitation that may happen with dementia due to Alzheimer's

REXULTI® (brexpiprazole), MDD

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation